Clinical trials: Nerve Condition
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
GBM, Glioblastoma Multiforme
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific…
- Trial name
- DCVax-L EAP (NCT02146066)
- Testing
- DCVax-L
- Where
- 27 sites in United States
- Sponsor
- Northwest Biotherapeutics
Ocular Motility Disorders, Strabismus
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)
This prospective, multicenter, multinational observational study evaluates the clinical validity of an AI-based quantitative eye movement analysis system (Glandy EOM) that analyzes smartphone-recorded 9-gaze videos.
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Trial name
- GLANDY-EOM-VAL (NCT07623837)
- Testing
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- THYROSCOPE INC.
Melanoma
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
The purpose of this study is to evaluate the safety and effectiveness of the intetumumab, alone and in combination with dacarbazine, in patients with stage 4 melanoma.
- Trial name
- NCT00246012
- Testing
- Intetumumab, Dacarbazine
- Where
- 32 sites in United States, Germany and 1 more
- Volunteers
- 144 people
- Sponsor
- Centocor, Inc.
Refractory Epilepsy
Clinical Trial of Vagus Nerve Stimulation for Treatment of Refractory Epilepsy
Evaluate the long-term clinical effectiveness and safety of the PINS vagus nerve stimulator to patients with refractory epilepsy.
- Trial name
- VNSRE (NCT02378792)
- Testing
- Vagus Nerve Stimulation
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Unilateral Carpal Tunnel Syndrome
Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves
This study is being done to see how well a new investigational medical device, the StimRouter (STR) System, will work to treat the chronic pain in people who have failed previous treatments for Carpal Tunnel Syndrome (CTS) pain…
- Trial name
- StimRouter (NCT00665132)
- Testing
- StimRouter System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bioness Inc
Down Syndrome, Obstructive Sleep Apnea
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome…
- Trial name
- NCT04801771
- Testing
- Inspire Upper Airway Stimulation (UAS) System
- Where
- 8 sites in United States
- Volunteers
- 57 people
- Sponsor
- Inspire Medical Systems, Inc.
Glioblastoma Multiforme
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
- Trial name
- NCT00093964
- Testing
- Cilengitide 500 mg, Cilengitide 2000 mg
- Where
- 17 sites in United States
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Malignant Melanoma
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A in patients with metastatic or unresectable melanoma.
- Trial name
- NCT01522664
- Testing
- DEDN6526A
- Where
- 6 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Genentech, Inc.
Malignant Melanoma, Skin
Intratumoral Administration of L19IL2/L19TNF
This Phase II study is an uncontrolled, multicenter, prospective study for patients with malignant melanoma of the skin in clinical stage III or stage IV M1a.
- Trial name
- NCT02076633
- Testing
- L19IL2+L19TNF
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Philogen S.p.A.
Cystocele
Nerve Access Tool Study
The purpose of this study is to assess the ability of the nerve access tool to facilitate nerve stimulation lead placement.
- Trial name
- NCT00942474
- Testing
- Facilitate nerve stimulation lead placement with the nerve access tool
- Sponsor
- MedtronicNeuro
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Carpal Tunnel Syndrome
Safety and Efficacy of a Device for the Relief of Pain Due to Carpal Tunnel Syndrome
Interventional study to evaluate efficacy and safety of an active splint.
- Trial name
- NCT03810326
- Testing
- CTR device (tradename named Xtend)
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yuinvent Innovations Ltd.
Malignant Melanoma
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.
- Trial name
- NCT00729950
- Testing
- MDX-010
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Glioblastoma
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT…
- Trial name
- GLORIA (NCT04121455)
- Testing
- Olaptesed pegol, Radiotherapy, Bevacizumab
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- TME Pharma AG
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Neuroendocrine Tumors, Carcinoid Syndrome
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients…
- Trial name
- SYMNET (NCT01234168)
- Where
- 57 sites in Czechia, France and 6 more
- Volunteers
- 340 people
- Sponsor
- Ipsen
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor…
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
- Trial name
- NCT03611868
- Testing
- Phase 1b: APG-115+pembrolizumab
- Where
- 21 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Ascentage Pharma Group Inc.
Type 2 Diabetes Mellitus
Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus
The primary study objective is to demonstrate the use of "Dragon Waves Resonant Home Care" Electronic Nerve Stimulator (DW1330) is associated with improvement of blood glucose control, as measured by change of glycated hemoglobin…
- Trial name
- NCT03102424
- Testing
- Transcutaneous Electrical Nerve Stimulator (DW1330)
- Where
- 6 sites in Taiwan
- Volunteers
- 160 people
- Sponsor
- Taiwan Resonant Waves Research Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.